CSF biomarkers that are typically altered in AD [ß-amyloid 42 (Aß42), ß-amyloid 40 (Aß40), total tau (t-tau) and phosphorylated tau (p-tau)] may offer another approach to understand underlying mechanisms and courses of patients with CAA (6). The gene discussed is MAPT; the disease is Alzheimer disease.